The combination of CAR-T-cell therapy with systematic administration of a CD39 antibody yielded promising anti-tumor efficacy against ovarian cancer, and even greater efficacy was observed when the antibody was administered in a secreted form. The gene discussed is ENTPD1; the disease is ovarian cancer.